Training of Ugandans in Basic and Translational Research on TB and Emerging Infectious Diseases

项目摘要 乌干达的研究基础设施在过去十年中大大扩展， 坎帕拉的大学（MU）已成为全球合作的主要学术机构之一。 研究结核病和新出现的传染病。目前，美国国立卫生研究院，疾病预防控制中心，盖茨基金会，惠康信托， 英国医学研究理事会和欧洲与发展中国家临床试验伙伴关系提供 为乌干达的结核病和其他传染病研究提供实质性支持，包括评估新的 诊断学;药物治疗方案;以及疫苗和发病机制及其相关因素的转化研究。 免疫力因此，大多数培训是在临床流行病学和研究设计，没有具体的 目标差距在实验室为基础的研究科学家，将成为教员，竞争力， 校外资助的研究项目。由于在基础和翻译培训方面存在差距， 研究结核病和新兴传染病，波士顿医学中心（BMC）/波士顿大学医学院 医学（BUSM）寻求并获得了福格蒂国际中心的资金，以资助能力 建筑在这个领域。在此期间，三名乌干达科学家接受了该方案的培训， 目前正在攻读研究生课程。该计划建立了协作联系，并巩固了联合 承诺由BMC/BUSM和MU共同指导乌干达受训人员。本计划资助的短期课程 该计划已成为必不可少的硕士和博士生的培训方案，并提供了一个 与教师讨论和进一步招聘的渠道。尽管取得了这些进展， 继续扩大基础研究和转化研究的培训机会。对于此更新申请， 我们将作出两项重大改变。首先，我们将针对那些打算进入一个 在MU博士课程;学员将被招募到一个或两个指定为发展的关键领域， MU教师和项目主任和科学主任。第二，罗格斯-新泽西医疗 学校（NJMS）已被添加为第二个培训地点。它的加入将提供专业的分子 耐药性机制和基础及转化免疫学。首先，我们的主要目标是 该计划将通过以下方式为学员提供基础研究技能和知识的强大背景 严格的有针对性的课程加上在特定研究领域的强化实验室培训。我们 培训计划是针对当前和未来的结核病和新兴传染病研究而量身定制的 这是乌干达乃至整个乌干达的需要。

PROJECT SUMMARY The research infrastructure in Uganda has expanded considerably in the last decade and Makerere University (MU) in Kampala has become one of the principal academic institutions worldwide for collaborative research on TB and emerging infectious diseases. Currently NIH, CDC, Gates Foundation, Wellcome Trust, British Medical Research Council and the European & Developing Countries Clinical Trials Partnership provide substantial support for TB and other infectious diseases research in Uganda, including evaluation of new diagnostics; drug treatment regimens; and vaccines and translational studies of pathogenesis and correlates of immunity. As such, most of the training is in clinical epidemiology and study design and none specifically targets the gap in laboratory-based research scientists that will become faculty members, competitive for extramurally funded research programs. Because of identified gaps in training in basic and translational research on TB and emerging infectious diseases, Boston Medical Center (BMC)/Boston University School of Medicine (BUSM) sought out and secured funding from the Fogarty International Center to fund capacity building in this area. During this period, three Ugandan scientists received training under the program and are currently pursuing further graduate studies. The program established collaborative links and solidified a joint commitment to co-mentorship of Uganda trainees by BMC/BUSM and MU. Short courses funded under this program have become essential to the training regimen of masters and PhD students and have provided a conduit for discussion with faculty and further recruitment. Despite these strides, there is still a pressing need to continue to expand training opportunities in basic and translational research. For this renewal application, we will make two significant changes. First, we will target medical school graduates who intend to enroll in a PhD program at MU; trainees will be recruited to one or two areas designated as critical for development by the MU faculty and the Program Directors and Scientific Directors. Second, Rutgers-New Jersey Medical School (NJMS) has been added as a second site of training. Its addition will provide expertise molecular mechanisms of drug resistance and basic and translational immunology. Above all, our main objective of the program will be to provide trainees with a strong background in basic research skills and knowledge through rigorous targeted coursework coupled with intensive laboratory training in a particular research area. Our training program is tailored to address the current and future TB and emerging infectious disease research needs of MU as well as Uganda as a whole.